VK2735 explained

VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. It is injectable and is being developed by Viking Therapeutics.[1] [2] [3]

Notes and References

  1. Web site: Mariam E Sunny . Bhanvi Satija . Viking Therapeutics notches success with weight-loss drug trial, shares double . Reuters . 2024-02-27 . 2024-03-09.
  2. Goldenberg . Ronald M. . Teoh . Hwee . Verma . Subodh . Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data . Current Opinion in Cardiology . Ovid Technologies (Wolters Kluwer Health) . 38 . 6 . 2023-08-21 . 0268-4705 . 10.1097/hco.0000000000001084 . 539–545. 37792556 .
  3. Goldenberg . Ronald M. . Gilbert . Jeremy D. . Manjoo . Priya . Pedersen . Sue D. . Woo . Vincent C. . Lovshin . Julie A. . Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists . Obesity Reviews . 25 . 3 . 2024 . e13663 . 1467-7881 . 10.1111/obr.13663 . 37968541 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "VK2735".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.